HARM Reduction Australia and ScriptWise are joining forces to host a national summit in Canberra on 23 May to "re-think outdated policies and increase access to opioid treatment".
The organisers noted that the cost burden of dispensing fees for opioid treatment medications such as methadone and buprenorphine is one of the most significant barriers to treatment for consumers.
Currently the ACT Government subsidises dispensing fees via a system that includes a modest consumer co-payment, but similar measures are not in place in other states and territories.
ScriptWise ceo Bee Mohamed said the new partnership is also an important opportunity to reduce the stigma around seeking treatment for both legal and illicit opioid dependency.
CLICK HERE for more details.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 18
